EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

Alzamend Neuro, Inc. (NASDAQ:ALZN) connected Tuesday announced the initiation of the archetypal of 5 Phase 2 objective studies of AL001, with the archetypal survey successful healthy quality subjects.

This survey follows the improvement of a caller caput coil by Tesla Dynamic Coils BV, a cardinal component of the objective trial.

In collaboration with Massachusetts General Hospital arsenic its objective proceedings site, Alzamend aims to research AL001 and its imaginable to present lithium much efficaciously successful the encephalon than marketed lithium salts.

The survey successful steadfast quality subjects volition service arsenic a baseline and assistance Alzamend to find the champion way guardant successful Alzheimer's, bipolar disorder, large depressive disorder, and post-traumatic accent upset patients by demonstrating AL001's targeted effectiveness and reduced systemic broadside effects.

Topline information is expected by the extremity of 2025.

Also Read: EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

Previous studies successful mice person shown that AL001 ensures amended encephalon absorption portion maintaining little levels of lithium successful the blood, paving the mode for safer and much businesslike treatments.

In March, Alzamend Neuro announced its plans to initiate a signifier 2 objective survey of AL001 for patients with post-traumatic accent upset successful the fourth 4th of 2025.

In November 2024, Alzamend Neuro finished analyzing a nonclinical study's last afloat information acceptable comparing encephalon and plasma lithium exposures betwixt AL001 and lithium carbonate successful Alzheimer's transgenic mice.

The survey progressive administering AL001 to 5XFAD mice, a recognized exemplary for Alzheimer's research, to comparison its effects against lithium carbonate, an FDA-approved and marketed API.

Mice received precocious oregon debased doses, scaled to humans, of AL001 and lithium carbonate implicit 14 days to observe pharmacokinetic steady-state cause conditions.

Last week, the company's committee of directors approved a one-for-nine reverse banal divided of its communal banal to support compliance with the minimum bid terms request of $1.00 per stock required to support continued listing connected the Nasdaq Capital Market.

Price Action: At the past cheque connected Tuesday, ALZN banal was up 6.57% to $5.49 during the premarket session.

Read Next:

• Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.

Get the latest banal investigation from Benzinga?